Corcept Therapeutics said on Monday its experimental combination ovarian cancer drug improved survival in patients with a ...

She believed that had she had a CA125 blood test earlier - CA125 is a protein in the blood and can be raised in women with ...

A common blood test for ovarian cancer is more likely to fall short for Black and Native American women, according to a new ...

A comparison of patients with and without BRCA gene mutations receiving prophylactic risk-reduction surgery suggest ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Corcept Therapeutics shares nearly doubled in premarket trading Monday after the company said it received positive data from its phase 3 ovarian cancer treatment trial. Shares rose 93% ahead of the ...

Corcept Therapeutics said on Monday its experimental ovarian cancer drug in combination with chemotherapy met the main goal of a late-stage trial.

Ovarian cancer—known as a silent killer due to its inability to showcase most of its symptoms—kills many women every year ...

A new study finds that a common blood test for ovarian cancer may miss some Black and Native American patients, delaying ...

A woman's story of literal strength shows how ovarian cancer can be missed—and the lighthearted recovery milestone every care ...

A common blood test may miss ovarian cancer in some Black and Native American patients, delaying their treatment, a new study ...

The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.